Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Says Barda 25 Million Funding on the New Website
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(290)
•••
Comment by Moonshiner592on Feb 06, 2021 2:41pm
101 Views
Post# 32493579

RE:RE:RE:RE:Says Barda 25 Million Funding on the New Website

RE:RE:RE:RE:Says Barda 25 Million Funding on the New Website
mopar1969 wrote:
Haven't found that. Found this so far:

Current Development Program

Claritas is working with Salzman Group to develop R-107 for the treatment of COVID-19 and other viral infections. Salzman Group has received $25M in federal funding to date for advancement of R-107 and R-100 for treatment of chlorine inhalational lung injury (“CILI”) and sepsis.

The government does not enjoy any commercial rights to the technology. The contract is part of efforts by ASPR’s Biomedical Advanced Research and Development Authority (“BARDA”) to develop medical products and procedures to protect health and save lives in a terrorist attack, including those using toxic industrial chemicals such as chlorine. The funding supported the advancement of R-107 in manufacturing, pharmacology, and toxicology.



It says "Salzman" got that funding... Kaly acquired  R107 from them .. which happened right before the the halt...



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities